Abstract
Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.
| Original language | English |
|---|---|
| Pages (from-to) | 675-684 |
| Number of pages | 10 |
| Journal | Dialysis and Transplantation |
| Volume | 32 |
| Issue number | 11 |
| State | Published - Nov 2003 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
- Transplantation
Cite this
Icodextrin Fulfills Unmet Clinical Need of PD Patients : Improved Ultrafiltration. / Hamburger, Richard J.; Kraus, Michael.
In: Dialysis and Transplantation, Vol. 32, No. 11, 11.2003, p. 675-684.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Icodextrin Fulfills Unmet Clinical Need of PD Patients
T2 - Improved Ultrafiltration
AU - Hamburger, Richard J.
AU - Kraus, Michael
PY - 2003/11
Y1 - 2003/11
N2 - Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.
AB - Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.
UR - http://www.scopus.com/inward/record.url?scp=0242710164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242710164&partnerID=8YFLogxK
M3 - Article
VL - 32
SP - 675
EP - 684
JO - Dialysis and Transplantation
JF - Dialysis and Transplantation
SN - 0090-2934
IS - 11
ER -